

**ITL Announces Significant Sales of its  
Recently Launched DonorCare® Needle Guard 2**

ITL BioMedical, a division of ITL that sets industry standards for the innovative design and production of biological sampling systems for human and animal use, is pleased to announce that after launching its highly innovative patented DonorCare® Needle Guard 2 mid-October the Company has already achieved significant sales in excess of one million products.

The product has now been launched and sold in both the US and Canada. As well as the considerable sales already made there are additional customer evaluations being carried out in other geographic regions.

ITL has been selling the first generation DonorCare Needle Guard for over 15 years and has sold in excess of 200 million units in over 50 countries.

First generation DonorCare Needle Guard set a global industry standard for whole blood collection needle guards. The highly innovative DonorCare Needle Guard 2 provides robust functionality with enhanced features including visual confirmation that the needle is safely locked in place, along with an audible click.

Bill Mobbs, Executive Chairman of ITL BioMedical commented “It is a great achievement by the team to have made such significant sales in important jurisdictions in such a short period of time.

“The product was well received at its launch at the AABB Conference in Orlando, Florida and we look forward to announcing further contract wins in the future.”

**About ITL BioMedical – ITLBioMedical.com**

ITL BioMedical is a division of ITL that sets industry standards for the innovative design and production of biological sampling systems for human and animal use. The Division’s patented medical devices focus on safety and process efficiency for end-users and their blood donors and patients in blood collection centers and healthcare markets worldwide. For more information or inquiries, visit ITLBioMedical.com

**ITL Limited ABN 16 088 212 088**  
**Unit 1, 63 Wells Road**  
**Chelsea Heights, Victoria, 3196**

ITL is an innovative diversified medical technology company that creates and manufactures leading edge medical devices for Operating Theatres, Bloodbanks and laboratories.

ITL’s patented medical devices are sold in over 50 countries and protect healthcare workers in millions of procedures annually.

ITL’s wholly owned subsidiary MyHealthTest creates and markets highly innovative direct to consumer pathology testing for major chronic diseases.



Ranked 16<sup>th</sup> most Innovative Company by the AFR  
Innovative Companies Awards

**Australian Securities Exchange**

Code: ITD

**Ordinary Shares**

95,928,314

**Board of Directors**

Bill Mobbs	Executive Chairman
Mark Peatey	Non-executive Director
Andrew Turnbull	Non-executive Director
Trevor Doolan	Chief Financial Officer

**ITL Contact**

Trevor Doolan	Company Secretary
Phone:	+61 3 8773 3050
Email:	<a href="mailto:info@itl-limited.com">info@itl-limited.com</a>

**[www.itl-limited.com](http://www.itl-limited.com)**

**Media**

Ben Knowles	Walbrook IR
Phone:	+61 426 277 760
Email:	<a href="mailto:ben.knowles@walbrookir.com.au">ben.knowles@walbrookir.com.au</a>

**About DonorCare® Needle Guard 2**

The DonorCare® Needle Guard 2 is designed for safe and fast needle withdrawal, immediately shielding the whole blood collection needle in a secure, one piece housing thereby reducing potential exposure to needle stick injury. Featuring a simple and user-friendly design, the product requires minimal training and can be easily incorporated into existing processes. ITL BioMedical's efficient product design enables manufacturers to pre-attach DonorCare® Needle Guard 2 onto blood bag tubing.

DonorCare® is a registered trademark of ITL Corporation, Melbourne, Australia. Copyright © 2016. All rights reserved.